Clinical Research Directory
Browse clinical research sites, groups, and studies.
Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank
Sponsor: Centre Hospitalier de PAU
Summary
The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1000
Start Date
2026-03-19
Completion Date
2036-04-01
Last Updated
2026-10-22
Healthy Volunteers
No
Conditions
Interventions
biobank
The following samples will be collected : * Serum samples and plasma sample: inclusion visit and follow up visit * Urines samples : inclusion visit and follow up visit * blood DNA: inclusion visit * Blood RNA: inclusion visit and follow up visit
Locations (11)
CH d'Annecy
Annecy, France
CHU de Bordeaux
Bordeaux, France
CH de Chalon sur Saône
Chalon-sur-Saône, France
Hospices Civils de Lyon
Lyon, France
APHP Avicenne
Paris, France
Hôpital Européen Georges Pompidou
Paris, France
Hôpital Paris Saint Joseph
Paris, France
CHU de Strasbourg
Strasbourg, France
CHU de Toulouse
Toulouse, France
CHRU de Tours
Tours, France
CH de Valenciennes
Valenciennes, France